SOURCE: Opexa Therapeutics, Inc.

Opexa Therapeutics, Inc.

September 07, 2016 08:30 ET

Opexa Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment Conference

Final Patient Visit Completed in Phase 2b Clinical Trial of Tcelna (imilecleucel-T) in Secondary Progressive Multiple Sclerosis; Top-Line Results Expected in Early Q4 2016

THE WOODLANDS, TX--(Marketwired - Sep 7, 2016) - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders, today announced that Neil K. Warma, President and Chief Executive Officer, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016, at 4:15 p.m. EDT in the Kennedy II room of the Lotte New York Palace Hotel in New York City.

Mr. Warma will provide an update on the Abili-T Trial, the Company's 190-patient Phase 2b clinical trial designed to evaluate the efficacy and safety of Tcelna® (imilecleucel-T) in patients with secondary progressive multiple sclerosis (SPMS). The final patient visit in Abili-T has been completed and top-line results are expected early in the fourth quarter of 2016.

A live webcast of the presentation can be accessed via the Investor Relations section of the Company's website at www.opexatherapeutics.com. An archive of the webcast will be available on the Company's website until December 12, 2016.

About Tcelna® (imilecleucel-T)

Tcelna is a first-in-class precision immunotherapy that is manufactured using ImmPath®, Opexa's proprietary T-cell technology platform, and is being studied in a Phase 2b clinical trial in patients with secondary progressive multiple sclerosis (SPMS). Tcelna aims to address the root cause of multiple sclerosis (MS) by programming the immune system to target myelin reactive T-cells to eliminate or regulate the cells, inhibiting further destruction of the myelin sheath and potentially enabling remyelination. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient's peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process, which is tailored to each patient's disease profile and immune response to myelin, triggers a potent immune response against specific subsets of autoreactive T-cells. Opexa has received Fast Track designation from the U.S. Food and Drug Administration for Tcelna in SPMS. The final patient visit has been completed in the Phase 2b trial and top-line results are expected early in the fourth quarter of 2016.

About Opexa Therapeutics

Opexa Therapeutics is a biopharmaceutical company developing personalized immunotherapies based on ImmPath®, its proprietary T-cell technology, with the potential to treat multiple sclerosis (MS) and other autoimmune diseases. The Company has completed a Phase 2b clinical trial of its lead product candidate Tcelna®, a personalized T-cell immunotherapy, in patients with secondary progressive MS. Opexa is also developing OPX-212 to treat neuromyelitis optica (NMO), a rare and serious autoimmune disorder that affects optic nerves and the spinal cord.

For more information, please visit Opexa Therapeutics' website at www.opexatherapeutics.com or follow company news on Twitter via @OpexaCEO or LinkedIn.

Source: Opexa Therapeutics, Inc.

Company Contact:

Camilla Zuckero

Opexa Therapeutics, Inc.

281-775-0600

Contact Information

  • Company Contact:

    Camilla Zuckero
    Opexa Therapeutics, Inc.
    281-775-0600